Calliditas Therapeutics | IPO Presentation Deck | 38 slides · page 34 of 38
The chart demonstrates a strong correlation (R^2=0.90) between proteinuria reduction and ESRD risk reduction, supporting the use of proteinuria as a surrogate endpoint.
Pitch deck · appendix_methodology · analyze_data · dense density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 chart 1/1 paragraph 2/2 source-note 1/1 title 1/1
Components 6
primary bubble paragraph paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1